<DOC>
	<DOCNO>NCT01578499</DOCNO>
	<brief_summary>This Randomized , Open-Label , Phase 3 trial brentuximab vedotin ( SGN-35 ) Versus Physician 's Choice ( Methotrexate Bexarotene ) Patients With CD30-Positive Cutaneous T-Cell Lymphoma</brief_summary>
	<brief_title>A Phase 3 Trial Brentuximab Vedotin ( SGN-35 ) Versus Physician 's Choice ( Methotrexate Bexarotene ) Patients With CD30-Positive Cutaneous T-Cell Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Mycosis Fungoides</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Anaplastic</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Cutaneous</mesh_term>
	<mesh_term>Lymphoma , Primary Cutaneous Anaplastic Large Cell</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Bexarotene</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Voluntary consent form Male female patient 18 year old diagnosis MF pcALCL Patients pcALCL receive prior radiation therapy least 1 prior systemic therapy ; patient MF receive least 1 prior systemic therapy Histologically confirm CD30+ disease central laboratory assessment pathology review Eastern Cooperative Oncology Group ( ECOG ) performance status â‰¤ 2 Female patient post menopausal , surgically sterile , agree practice 2 effective method contraception agree practice true abstinence , line prefer usual lifestyle subject Male patient agree practice effective barrier contraception agree practice true abstinence , line prefer usual lifestyle subject Clinical laboratory value specify protocol A concurrent diagnosis systemic ALCL , non Hodgkin lymphoma ( exclude LyP ) Sezary syndrome B2 disease Patients cardiovascular condition specify protocols Patients history another primary malignancy remission least 3 year Known active cerebral/meningeal disease , HIV infection , hepatitis B Hepatitis C infection Oral retinoid therapy indication within 3 week study entry Corticosteroid therapy within 3 week immunosuppressive chemotherapy antibodydirected immunoglobulinbased immune therapy ( eg , immunoglobulin replacement , monoclonal antibody therapy ) within 12 week first dose study drug Female patient lactate breastfeed positive serum pregnancy test screen period positive urine pregnancy test Day 1 cycle Previous receipt brentuximab vedotin Please note additional inclusion exclusion criterion . The study center determine meet criterion . Site personnel explain trial detail answer question may qualify study . You decide whether wish participate . If qualify trial , site personnel explain reason .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>brentuximab vedotin</keyword>
	<keyword>ALCANZA</keyword>
</DOC>